Davies

Life Sciences

Our experienced and multi-disciplinary Life Sciences practice draws on our venture capital, securities, corporate, commercial and tax expertise to assist our life sciences clients with their strategies and agreements ranging from collaboration, research, material transfer, joint venture, distribution, manufacturing and licensing to public offerings, private placements, mergers and acquisitions and unique financing structures.

Given the international scope of their businesses, our life sciences clients have also come to appreciate the value of our multijurisdictional practice and perspective. Also, our clients are actively developing breakthrough cures or innovative treatments for indications including: Alzheimer's Disease, cancer, diabetes, anemia, cerebral amyloid angiopathy, as well as medical technologies to assist in the fields of cardiovascular disease and orthopaedic surgery. Some offer drugs for urology, endocrinology and women's health, while others develop and sell diagnostic products throughout the world.

Our Clients

We represent virtually all categories of client in our Life Sciences practice, including:

  • Small, medium and large-sized bio-pharmaceutical, drug discovery and medical device companies;
  • Medical technologies and diagnostic products companies;
  • Venture capitalists;
  • Institutional investors; and
  • Investment banks.

Organizational Leadership

Several members of our practice have written extensively and appeared on panel presentations on life sciences and biotechnology issues.

Recent Work

  • Pershing Square Capital and Valeant Pharmaceutical's proposed acquisition of Allergan Inc.
  • Actavis plc's proposed US$25-billion acquisition of Forest Laboratories Inc.

VIEW ALL

Key Contacts

Richard Cherney Richard Cherney
Partner
Montréal
514.841.6457

VIEW ALL